BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 1301584)

  • 1. Objective response of superficial bladder tumors to intravesical treatment (including review of response of marker lesions).
    Bouffioux C; van der Meijden A; Kurth KH; Jakse G; Bono A; Hall R; Oosterlinck W; Sylvester R
    Prog Clin Biol Res; 1992; 378():29-42. PubMed ID: 1301584
    [No Abstract]   [Full Text] [Related]  

  • 2. When does superficial bladder cancer resist intravesical therapy?
    Vögeli T; Ackermann R
    Semin Urol; 1990 Nov; 8(4):248-53. PubMed ID: 2284531
    [No Abstract]   [Full Text] [Related]  

  • 3. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
    Soloway MS; Jordan AM; Murphy WM
    Prog Clin Biol Res; 1989; 310():215-36. PubMed ID: 2505268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracavitary treatment of transitional cell carcinoma of the bladder: questions and lessons after 27 years of experience.
    Kurth KH; Sylvester R; de Pauw M; ten Kate F
    Prog Clin Biol Res; 1989; 310():125-45. PubMed ID: 2672012
    [No Abstract]   [Full Text] [Related]  

  • 5. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Endovesical chemotherapy for superficial bladder tumors].
    Chopin D; Gattegno B
    Prog Urol; 2001 Nov; 11(5):1047-64. PubMed ID: 11769074
    [No Abstract]   [Full Text] [Related]  

  • 7. Intravesical chemoprophylaxis of superficial transitional cell carcinoma of the bladder. When should the drug be given?
    Bouffioux C
    Prog Clin Biol Res; 1985; 185B():47-55. PubMed ID: 4034591
    [No Abstract]   [Full Text] [Related]  

  • 8. Intravesical chemotherapy. Treatment selection, techniques, and results.
    Richie JP
    Urol Clin North Am; 1992 Aug; 19(3):521-7. PubMed ID: 1636236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytological surveillance of carcinoma in situ during and after intravesical chemotherapy.
    Roth S; Rathert P
    Prog Clin Biol Res; 1989; 303():523-4. PubMed ID: 2780660
    [No Abstract]   [Full Text] [Related]  

  • 10. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
    Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
    Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response.
    van der Heijden AG; Moonen PM; Cornel EB; Vergunst H; de Reijke TM; van Boven E; Barten EJ; Puri R; van Kalken CK; Witjes JA
    J Urol; 2006 Oct; 176(4 Pt 1):1349-53; discussion 1353. PubMed ID: 16952629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photodynamic therapy for refractory superficial bladder cancer: long-term clinical outcomes of single treatment using intravesical diffusion medium.
    Manyak MJ; Ogan K
    J Endourol; 2003 Oct; 17(8):633-9. PubMed ID: 14622483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer.
    Puri R; Palit V; Loadman PM; Flannigan M; Shah T; Choudry GA; Basu S; Double JA; Lenaz G; Chawla S; Beer M; Van Kalken C; de Boer R; Beijnen JH; Twelves CJ; Phillips RM
    J Urol; 2006 Oct; 176(4 Pt 1):1344-8. PubMed ID: 16952628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is intravesical chemotherapy for superficial bladder cancer still justified?
    Okeke AA; Probert JL; Gillatt DA; Schwaibold H
    BJU Int; 2005 Oct; 96(6):763-7. PubMed ID: 16153195
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment and follow-up of superficial bladder cancer].
    Raitanen M
    Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
    Huncharek M; McGarry R; Kupelnick B
    Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Quantitative immunocytology as a marker for indications and follow-up of recurrence prevention of superficial urinary bladder cancers].
    Schneider AW; Huland E; Huland H
    Urologe A; 1989 Sep; 28(5):289-91. PubMed ID: 2815438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intravesical chemotherapy in superficial tumors of the bladder].
    Lundbeck F
    Ugeskr Laeger; 1983 Feb; 145(9):641-4. PubMed ID: 6857826
    [No Abstract]   [Full Text] [Related]  

  • 19. [Low-grade, low-stage transitional carcinoma of the bladder. Analysis of 147 cases].
    Escudero Barrilero A; Gutiérrez Sanz-Gadea C; Hernández Fernández C; Mateos Torres A; Maganto Pavón E; Mayayo Dehesa T
    Actas Urol Esp; 1985; 9(2):135-46. PubMed ID: 3925729
    [No Abstract]   [Full Text] [Related]  

  • 20. Intravesical therapy.
    Herr HW
    Hematol Oncol Clin North Am; 1992 Feb; 6(1):117-27. PubMed ID: 1556045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.